ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Antibiotics developer Entasis Therapeutics seeks to go public

by Ryan Cross
August 26, 2018 | APPEARED IN VOLUME 96, ISSUE 34

 

This year’s biotech stock boom continues as Entasis Therapeutics plans to raise $86 million in an initial public offering. Entasis was spun off from AstraZeneca in 2015 when the drugmaker dissolved its antibiotics research group. Now Entasis is developing antibiotics for tough-to-kill Gram-negative bacteria, particularly ones that are resistant to multiple drugs. So far it has three drugs in human clinical ­trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment